Cancer NetworkOriginal article
<![CDATA[CAR T-Cell Therapy Earns FDA IND Clearance in Large B-Cell Lymphoma]]>
RegulatoryapprovedC-CAR039Positive
AI Analysis
Summary
The FDA has granted IND clearance for C-CAR039, a CD19/CD20 bispecific CAR T-cell therapy, enabling investigational studies in relapsed/refractory large B-cell lymphoma patients.
Outcome Details
FDA IND clearance granted for C-CAR039, a CD19/CD20 bispecific CAR T-cell therapy
Importance:6/10
Sentiment:
0.70
CAR T-cell therapyFDA clearanceIND approvalLarge B-cell lymphomaOncologyBispecific antibody
Read the original article
Published by Cancer Network on August 17, 2026 10:00 PM